Among the most notable aspects of the Covid-19 vaccine race was who won it: Pfizer and two small biotechs, while most of the world’s largest and oldest vaccine makers either waited too long or picked older and ultimately less effective technologies. Since then, there’s been a minor gold-rush for mRNA among legacy makers. Last year, GSK expanded a collaboration with CureVac, one of the first mRNA startups, and Sanofi bought another called Translate Bio for $3.2 billion.
Now Merck, which reportedly turned down an opportunity to partner on Moderna’s vaccine early in the pandemic, is getting in on the game.
On Tuesday, the company announced a deal to develop mRNA-based vaccines and therapies with Orna Therapeutics, a Cambridge-based startup that launched during the pandemic with a slightly different take on mRNA technology. Merck will pay Orna a $150 million upfront fee, invest $100 million in a new funding round for the company, and offer $3.5 billion in longer-term milestones.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect